Seeing Is Believing
Currently out of the existing stock ratings of Alan Carr, 59 are a BUY (95.16%), 2 are a SELL (3.23%), 1 are a HOLD (1.61%).
Analyst Alan Carr, currently employed carries an average stock price target met ratio of 60.69% that have a potential upside of 28.61% achieved within 227 days. Previously, Alan Carr worked at NEEDHAM.
Alan Carr’s has documented 138 price targets and ratings displayed on 18 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 13-May-2022.
Analyst best performing recommendations are on BHVN (BIOHAVEN PHARMACEUTICAL HOLDING CO LTD).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 2/27/2014. The price target of $22 was fulfilled within 6 days with a profit of $4.64 (26.73%) receiving and performance score of 44.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$55
$7.75 (16.40%)
$59
14 days ago
(06-Nov-2024)
9/15 (60%)
$4.81 (9.58%)
109
Buy
$84
$36.75 (77.78%)
$84
14 days ago
(06-Nov-2024)
8/16 (50%)
$33.81 (67.36%)
214
Hold
$53
$5.75 (12.17%)
$53
14 days ago
(06-Nov-2024)
9/11 (81.82%)
$2.81 (5.60%)
180
Hold
$59
$11.75 (24.87%)
$64
3 months 14 days ago
(06-Aug-2024)
6/8 (75%)
$9.67 (19.60%)
38
Buy
$94
$46.75 (98.94%)
$112
3 months 14 days ago
(06-Aug-2024)
3/11 (27.27%)
$44.67 (90.55%)
27
What Year was the first public recommendation made by Alan Carr?